Sucking up talent out of Novartis, a booming Rubius adds another $100 million mega-round to the kitty
Just 8 months after putting the finishing touches to a $120 million round, Flagship startup Rubius Therapeutics is back at the money well, drawing up another big mega-round of $100 million.
This time, with more than $220 million to the good since jumping off the starting line, Rubius describes the raise as a “crossover round.” So does that mean that there’s an S-1 under construction?
Not exactly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
